Comprehensive characterization of CDK inhibitors using a complete panel of all 20 human cyclin-dependent kinases
IC50 profiling against 320 protein kinases: Improving the accuracy of kinase inhibitor selectivity testing.
Application of biochemical and cellular activity assays for the characterization of inhibitors targeting disease-relevant mutants of the EGF receptor
